Early Serum Protein Decline During Zolbetuximab Therapy in Gastroesophageal Adenocarcinoma: A Real-World Signal Suggestive of Protein-Losing Enteropathy (ACG 2026) - Aug 29, 2026 - Abstract #P6668; Pres time: Oct 13, 2026; 10:30 AM - 04:00 PM; Location: Exhibit Halls A - D (Level 3); "Twenty-four patients were included. Serum albumin declined in all patients, and total protein declined in 23/24 (95.8%) immediately following treatment initiation (Figure 1). After the first cycle, median albumin decreased by 0.9 g/dL (22.8%), and total protein decreased by 1.5 g/dL (23.7%) from baseline (Figure 2)."
Clinical • Real-world • Real-world evidence • Gastroesophageal Junction Adenocarcinoma • Nephrology • Oncology • Renal Disease • Solid Tumor • CLDN18
|
|
Fares Jamal MD 1; Cody Eslinger MD 2; Abdullah Alsulaiman MD 2; Tanois Bekaii-Saab MD 2; Hao Xie MD 3; Daniel Ahn DO 2; Jason S. Starr DO 4; Jake Jochum PA-C 3; Nguyen H. Tran MD 3; Mojun Zhu MD 2; Ben George MD 3; Caitlin B. Conboy MD 3; Conor D.J. O'Donnell MBBCh 4; Jamie Bering MD 2; Harry H. Yoon MD 3; Mohamad Bassam Sonbol MD 2
|